NIMU-OTC BB...trading around .24......another vso (very small one) is showing some activity today...file it away and look at it when you have time...pretty interesting:
Non-Invasive Monitoring Systems Announces First
Quarter Profits and Patent of Its Therapeutic Motion
Platform
MIAMI BEACH, Fla.--(BUSINESS WIRE)--Dec. 15, 2000--Non-Invasive Monitoring Systems, Inc. (NIMS) (OTC:NIMU -
news), announces results for the first quarter ended October 31, 2000.
For the quarter ended October 31, 2000, NIMS reported a profit of approximately $37,000 compared to a loss of approximately
$99,000 for the quarter ended October 31, 1999. For the quarter ended October 31, 2000, total revenue was approximately
$257,000 compared to approximately $83,000 in quarter ended October 31, 1999.
Non-Invasive Monitoring Systems, Inc. (the ``Company'' or ``NIMS'') is engaged in the research and development of computer
assisted, non-invasive monitoring devices and related software designed to detect abnormal respiratory, cardiac, and other medical
conditions from sensors placed externally on the body's surface. These devices provide diagnostic information regarding
cardiorespiratory and sleep disorders in infants, children and adults; in addition, alarms are sounded for adverse cardiac and
respiratory events in critically ill patients. In addition, NIMS has developed a therapeutic motion platform that imparts periodic
acceleration to the body.
During the first quarter 2000, NIMS continued development of the LifeShirt system, on behalf of VivoMetrics, Inc. (formerly
called LifeShirt.com, Inc.). This product incorporates an array of NIMS' patented sensor technologies for continuous monitoring of
cardiopulmonary signs into a wearable garment along with an electrocardiogram and position sensor. NIMS designed and tested
an electronic module for the LifeShirt which interfaces to flash memory and a PDA worn on the body. Over 40 physical and
emotional signs of health and disease together with the patient's symptoms, mood and activities are sent to VivoMetrics, Inc.'s data
collection center for quality control, review, report generations, and data storage. Data analysis is based upon an upgrade of
software written by NIMS. In August, 2000, NIMS entered into agreements to assign its patents relating to the LifeShirt system
technology to VivoMetrics, Inc. while licensing to NIMS the rights to the sale of products in bedside monitoring devices except for
ambulatory monitoring. Furthermore, VivoMetrics, Inc. signed a Research and Development agreement with the Company, which
the Company anticipates, will wholly fund NIMS' operations through August 2001. NIMS holds an equity position in VivoMetrics,
Inc. as well as future royalties based upon revenues of VivoMetrics, Inc. arising from the sales and marketing of the LifeShirt
system. Testing of the LifeShirt system in clinical drug evaluations is scheduled to begin in February 2001. Reference to the
LifeShirt system appeared in December issues of South Florida The Business Journal, BusinessWeek, Time, and Newsweek
magazines.
NIMS is continuing its development of a therapeutic motion platform that produces repetitive head to foot motion, a new direction
for the Company's business. In experiments, this device produces ``Non-Invasive Motion Ventilation,'' a new means to achieve
ventilation at breath volumes lower than natural breathing and with rates that are more rapid. This modality does not impose
positive pressure on the lungs either in normal or diseased lungs thereby reducing potential for damage to lung tissue as often
occurs with conventional positive pressure mechanical ventilation. Dr. Jose Adams, Chief of Neonatology, Mt. Sinai Medical
Center, Miami Beach, FL Beach, published two papers on these findings in the December issue of Journal of Applied Physiology.
Further, these studies suggested that the motion platform appeared to release nitric oxide from the inner lining of blood vessels.
Nitric oxide is the most powerful dilator of blood vessels in the body and has a major beneficial role in the prevention and
treatment of coronary artery disease, angina pectoris, hypertension, chronic heart failure, arteriosclerosis, stroke, and venous
thrombosis. The release of nitric oxide during aerobic exercise is believed to account for the beneficial effects of exercise on the
heart. During the quarter ended October 31, 2000, the Company fabricated an improved, prototype adult motion platform for
testing purposes. Monitoring of the digital pulse revealed findings consistent with release of significant quantities of nitric oxide
from the inner lining of blood vessels in normal adults who lay quietly on the device while headward to footward motion was
applied with the platform.
NIMS was notified that the ``Reciprocating Movement Platform for Shifting Subject to and fro in Headwards-Footwards
Direction'' and its applications were awarded US Patent 6,155,976 on December 5, 2000. NIMS also has a Provisional Patent
Pending on further applications of the motion platform. The Company is exploring means to bring this device to market by itself
and with other companies.
This press release contains, in addition to historical information, forward-looking statements regarding NIMS which represent
NIMS' expectations of benefits including but not limited to statements regarding industry performance, the Company's operations,
performance, financial condition, business strategies, margins and sales information, that involve risks and uncertainties. The
Company's actual results could differ materially. For this purpose, any statements contained in this release that are not statements
of historic fact may be deemed to be forward-looking statements. These statements, by their nature, involve substantial risks and
uncertainties, certain of which are beyond the Company's control, and actual results could differ materially depending on a variety
of important factors, including those described in this release and the Company's filings with the Securities and Exchange
Commission.
Consolidated Financial Summary
2000 1999
First 3 Months Year Ended October 31
Total Revenue $256,595 $83,041
Net Income (Loss) $36,900 ($99,265)
Income (Loss per Share) $0.002 ($0.005)
Number of Shares Outstanding 21,514,726 21,514,726
Contact:
Non-Invasive Monitoring Systems, Inc., Miami Beach
James Wong Chong, 305/534-3694
nims@respitrace.com |
